Middletown, NJNCT06563479Now EnrollingIRB Ready

Throat Cancer Clinical Trial in Middletown, NJ

Access cutting-edge throat cancer treatment through this phase 3 clinical trial at a research site in Middletown. Study-provided care at no cost to qualified participants.

Sponsored by Memorial Sloan Kettering Cancer Center

Quick Self-Assessment

See if you qualify for this Middletown location

Preparing your pre-screening questions…

Expert Care in Middletown

Access throat cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related throat cancer treatment provided free

Apply for This Middletown Location

Check if you qualify for this throat cancer clinical trial in Middletown, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Middletown

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Middletown site if eligible
  4. 4Begin participation

About This Throat Cancer Study in Middletown

The researchers are doing this study to find out if a personalized approach to chemoradiation therapy (which may include a lower dose of radiation) is as effective as the standard chemoradiation therapy in people with HPV-positive throat cancer. Other purposes of this study include looking at the following: * Whether a lower dose of radiation in combination with standard chemotherapy causes fewer side effects than the standard dose of radiation therapy in combination with standard chemotherapy

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Pathologically (histologically or cytologically) proven diagnosis of HPV associated squamous cell carcinoma of the oropharynx (tonsil, base of tongue, or oropharyngeal walls) or squamous cell carcinoma with an unknown primary. Surgical removal of primary site is allowed.
Patients must test positive for both p16 expression (70% nuclear and cytoplasm expression; Ventana Medical Systems) and mRNA HPV in situ hybridization (RNAscope® 2.5 HD Reagent kit (Advanced Cell Diagnostics, Inc, Hayward, CA). Any CLIA certified testing method can be used.
Clinical stage Tx-2, N1-2c (AJCC, 7th ed.) without evidence of distant metastasis based on FDG PET/CT.
ECOG Performance Status of 0-1 or KPS \>/=70
Adequate hematologic function within 30 days prior to registration, defined as follows:
White Blood Count (WBC) ≥ 2 K/mcL
Absolute neutrophil count (ANC) ≥ 1,500 cells/mm\^3
Platelets ≥ 100,000 cells/mm\^3
Hemoglobin ≥ 10.0 g/dl
Adequate renal function within 30 days prior to registration, defined as follows: o Serum creatinine \< 1.5 mg/dl or creatinine clearance (CC) ≥ 50 ml/min determined by 24-hour collection or estimated by Cockcroft-Gault formula: CCr male = \[(140 - age) x (wt in kg)\] \[(Serum Cr mg/dl) x (72)\] CCr female = 0.85 x (CrCl male)
Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential
The patient must provide study-specific informed consent prior to study entry
Optional section of the protocol: Patients must be able to undergo MRI scans, i.e. not claustrophobic

Exclusion Criteria

Patients with prior head and neck radiation therapy where there is \>30% overlap with the current head and neck radiation fields. Exceptions can be made if determined by the PI/Co-PI that the patient can proceed with protocol activities
Patients whose tumors are borderline T4 based on anterior tumor extension to the extrinsic muscles of the tongue
Patients with simultaneous primary cancers outside of the oropharynx o Note: Exceptions can be made for patients with simultaneous primaries outside the oropharynx if determined by the PI/Co-PI the patient can proceed with protocol activities
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for 3 years or if cure rate from treatment at 5 years to be 90% or greater o Note: Exceptions can be made for patients with prior malignancies outside the oropharynx if determined by the PI/Co-PI the patient can proceed with protocol activities.
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable
No particle therapy
Patients who are deemed non-compliant to all the protocol related activities
Contraindications to receive either cisplatin or the combination of carboplatin/5-fluorouracil at the prescribed doses.
Severe, active co-morbidity defined as follows:
Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
Transmural myocardial infarction within the last 6 months
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration
Hepatic Insufficiency resulting in clinical jaundice and/or coagulation defects

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Middletown?

Yes, this clinical trial (NCT06563479) has an active research site in Middletown, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Throat Cancer Treatment Options in Middletown, NJ

If you're searching for throat cancer treatment options in Middletown, NJ, this clinical trial (NCT06563479) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Middletown research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced throat cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all throat cancer clinical trials near you to find additional studies recruiting in your area.

More Head and Neck Cancer Trials in Middletown, NJ

See all head and neck cancer clinical trials recruiting in Middletown — not just this study.

Browse Head and Neck Cancer Trials in Middletown →

Browse More Trials by Condition

Head and Neck Cancer TrialsOsteoarthritis TrialsAll Conditions →

Ready to Join in Middletown?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Middletown, NJ